IL-4Rα antibodies are only effective in subsets of asthmatics and atopic dermatitis patients, and so a similar issue remains as to whether antibodies that block LIGHT will exert activity in those unresponsive subjects. This evidence concerns the gene TNFSF14 and atopic eczema.